| Prev Close | 12.58 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 8.67 / 14.55 |
| Avg Volume | 896.30K |
| Exchange | NASDAQ |
| Shares Outstanding | 109.36M |
| Market Cap | 1.32B |
| EPS | 0.50 |
| P/E Ratio | 14.71 |
| Div & Yield | N.A. (N.A) |
Latest News
Innoviva, Inc. Prices Offering Of $175 Million Of 2.50% Convertible Senior Notes
Innoviva, Inc. (NASDAQ: INVA) (the "Company" or "Innoviva") today announced the pricing of $175 million aggregate principal amount of the Company's 2.
Innoviva Announces Proposed Offering Of $175 Million Of Convertible Senior Notes
Innoviva, Inc. (NASDAQ: INVA) (the "Company" or "Innoviva") today announced its intention to offer, subject to market conditions and other factors, $175 million aggregate principal amount of convertible senior notes due...
Innoviva Reports Strong Second Quarter 2017 Financial Results
Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the second quarter of 2017.
GSK Submits EU Filing For Extended Use Of Relvar Ellipta In Patients With Controlled Asthma On An ICS/LABA Combination
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced a submission to the European Medicines Agency (EMA) for the extended use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol,...
Innoviva To Report First Quarter Financial Results On July 26 At 5:00 P.m. EDT
Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the second quarter ended June 30, 2017 after market close on Wednesday, July 26, 2017.
Interesting INVA Put And Call Options For August 18th
Investors in Innoviva Inc saw new options begin trading this week, for the August 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INVA options chain for the new August 18th contracts and identified one put and one call contract of particular interest.
INVA Crosses Above Average Analyst Target
In recent trading, shares of Innoviva Inc have crossed above the average analyst 12-month target price of $12.00, changing hands for $12.31/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Innoviva To Participate In Bank Of America Merrill Lynch Healthcare Conference On May 17
Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W.
Relvar Ellipta Significantly Improved Asthma Control In Salford Lung Study Patients Compared With Their Usual Care
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva Inc (NASDAQ: INVA) today announced positive results from the innovative Salford Lung Study (SLS) in asthma, carried out amongst 4,233 patients treated by their own General...
Innoviva Reports First Quarter 2017 Financial Results
Innoviva, Inc. (NASDAQ: INVA) today reported financial results for the first quarter of 2017.
Short Interest In Innoviva Falls 51.5%
The most recent short interest data has been released for the 04/13/2017 settlement date, which shows a 9,926,546 share decrease in total short interest for Innoviva Inc , to 9,337,021, a decrease of 51.53% since 03/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Innoviva To Report First Quarter Financial Results On April 27 At 5:00 P.m. EDT
Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the first quarter ended March 31, 2017 after market close on Thursday, April 27, 2017.
Sarissa Lawsuit Likely After Innoviva Claims Win Over Dissidents
Sarissa was seeking election of three nominees at the pharmaceutical company that the activist claims is being run for management's benefit.
Innoviva Announces Preliminary Results Of Annual Meeting
Innoviva, Inc. (the "Company" or "Innoviva") (NASDAQ: INVA) is pleased to announce that, based on the advice of its proxy solicitor, the Company believes shareholders voted to reelect all seven of Innoviva's director...
Innoviva Urges Shareholders To Vote "FOR" All Of Innoviva's Value-Creating Directors On The WHITE Proxy Card TODAY
Innoviva, Inc. (the "Company" or "Innoviva") (NASDAQ: INVA) today called upon shareholders to make the clear choice to vote FOR the Company's Board of Directors (the "Board").
Innoviva Issues Statement On Upcoming Annual Meeting Of Stockholders
Innoviva, Inc. (the "Company" or "Innoviva") (NASDAQ: INVA) today summarized for shareholders the clear and compelling reasons to vote FOR its nominees at the Company's upcoming Annual Meeting of Stockholders to be held on...
Sarissa Urges Shareholders To See Through Innoviva's Last Minute Flip-Flop On Cost Cuts; Notes Conspicuous Absence Of Promises To Fix Bad Corporate Governance
GSK SHOULD SEEK SARISSA'S OPINION ON INNOVIVA; GSK SHOULD NOT DECIDE HOW TO VOTE BEFORE HEARING SARISSA'S SIDE
With Strong And Consistent Growth In Profits, Innoviva Has Been Able To Deliver Increasing Returns To Shareholders - Including Capital Returns Of More Than $210 Million To Investors Since The First Quarter Of 2015. (Graphic: Business Wire)
Innoviva, Inc. (the "Company" or "Innoviva") (NASDAQ: INVA) today announced its Board of Directors has issued the following letter to shareholders in connection with the upcoming Annual Meeting of Stockholders to be held on...
Innoviva To Undertake Comprehensive Review Of Its Cost And Executive Compensation Structures
Innoviva, Inc. (the "Company" or "Innoviva") (NASDAQ: INVA) issued the following statement ahead of its upcoming Annual Meeting of Stockholders to be held on April 20, 2017: Innoviva strives to engage with all of...
Sarissa Capital Files Presentation In Proxy Contest With Innoviva
Sarissa believes Innoviva directors have breached their fiduciary duties by overpaying executives and overpaying themselves
Egan-Jones Supports All Three Sarissa Capital Nominees For Innoviva Board
All three proxy governance firms support Sarissa Capital and recommend Innoviva shareholders VOTE ON THE GOLD CARD
Sarissa Capital Is Concerned That Innoviva Will Waste Shareholder Money On Imprudent Acquisitions
Sarissa Capital is worried that acquisitions by Innoviva will irreparably destroy shareholder value
Sarissa Capital Compelled To Clarify Egregious Misstatements Made By Innoviva
ISS and Glass Lewis both recommend that Innoviva shareholders vote on Sarissa's GOLD PROXY CARD
